Replimune Group, Inc. REPL

Rank #2210 · Nasdaq · $1.5B market cap

⚠ Going-concern flag — the auditor (PricewaterhouseCoopers LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

29.1

P/E

-6.0

P/B

3.95

ROE

-66.0%

Op. Margin

–%

Debt Ratio

36%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Weak

P/E -6.0x, P/B 3.95x. Ranks in the top 74% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -66.0%. Ranks in the top 91% of the universe.

Safety ★★★★☆

Excellent

Debt ratio 36%. Ranks in the top 19% of the universe. Under 100% is generally considered a safe level.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2019	–	$-0.0B	$-0.0B	$-0.0B	–	-143
2021	–	$-0.1B	$-0.1B	$0.1B	–	37
2022	–	$-0.1B	$-0.1B	$0.2B	–	24
2023	–	$-0.1B	$-0.1B	$0.5B	–	10
2024	–	$-0.2B	$-0.2B	$0.4B	–	22
2025	–	$-0.2B	$-0.2B	$0.6B	–	20
2026	–	$-0.3B	$-0.2B	$0.4B	–	36

← See the full screener